Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Grillo, F; Fassan, M; Sarocchi, F; Fiocca, R; Mastracci, L.
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
World J Gastroenterol. 2016; 22(26):5879-5887 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Sarocchi Francesca

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focuses on HER2 in gastric carcinogenesis, on optimal evaluation of HER2 and on the possible causes which may contribute to inaccurate HER2 evaluation. Similarly to breast cancer HER2 evaluation, standardization of HER2 testing in gastric cancer is necessary in diagnostic practice. The three principle aspects which require consideration are: (1) the choice of sample with regards to cancer morphology - intestinal vs diffuse areas; (2) the choice of scoring criteria - use of HER2 scoring criteria specific for gastric cancer; and (3) the choice of HER2 evaluation methods - use of an algorithm in which both immunohistochemistry and in situ hybridization play a role. Problematic issues include: (1) pre-analytic variables with particular emphasis on fixation; (2) recommended methodology for HER2 assessment (immunohistochemistry vs in situ hybridization); (3) HER2 heterogeneity both within the primary tumor and between primary tumor and metastases; (4) reliability of biopsies in HER 2 evaluation; and (5) quantity of sample (FFPE blocks from surgical specimens or endoscopic biopsies) necessary for an adequate assessment.
Find related publications in this database (using NLM MeSH Indexing)
Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - metabolism
Biopsy -
Carcinogenesis -
Esophagogastric Junction -
Humans -
Immunohistochemistry -
In Situ Hybridization -
In Situ Hybridization, Fluorescence -
Patient Selection -
Receptor, ErbB-2 - metabolism
Stomach Neoplasms - drug therapy
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Trastuzumab - therapeutic use

Find related publications in this database (Keywords)
Gastric cancer
© Med Uni Graz Impressum